Conjugates useful in the treatment of prostate cancer
US5998362A · kind A · utility
50Cited by
10References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 9, 1997 |
| Grant date | Dec 7, 1999 |
| Priority date | — |
| Expiry date | Sep 9, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.